Hosted by PwC’s Life Sciences & Deals Practice, join thought leaders and investors from across healthcare to discuss how data and technologies are changing the way medicines and devices are developed and brought to market, and how these innovations will impact deal flow and value creation in our industry. Inspiring keynotes. Panel debates. Collaborative workshops. Curated private meetings.
Our program opens with a networking breakfast and concludes with a formal dinner at Restaurant Daniel. The following agenda is designed for attendance of up to 50 participants. All events take place in the Carlyle Hotel’s Trianon and Versailles Suites, unless otherwise noted. Times are subject to change.
This event is made possible through the assistance and support of PwC
Representatives of invited companies share strategically important lessons from a recent transaction. Mr. Schwartz will discuss the strategy evolution that helped deliver 23andMe’s recent data licensing agreement with Genentech. How might this deal formula inform your own company strategy?
Arivale CEO Clayton Lewis will offer a captivating vision of how the industry is changing, particularly as technology, patient data and consumerism become more important. He will discuss Arivale’ s innovative strategy to promote “scientific wellness,” which seeks to disrupt traditional and clinical pathways for treating chronic illnesses. Mr. Lewis is also a Partner at Maveron, the “consumer-only” venture firm based in Seattle. Q&A.
What curative value does a genetically tailored therapeutic have if the patient cannot stay on the protocol necessary to administer it? Jean-François Beaulé studies behavior science to help UnitedHealthcare assess and design innovative health plans that also support things like protocol compliance and healthy decision-making. He will discuss how he uses data, information and analytics to drive such assessments, leveraging what he calls “purposeful data” to empower “health ownership” among individuals. Includes Q&A.
How we measure success is changing; it is no longer a function of developing IP, clearing regulatory hurdles and generating revenue off an Rx. Today data is as valuable as a formulation. How is the power of consumer-generated data influencing how we evaluate strategic partnerships and the most valuable deals in the market? Given the growing importance of such data, among the technology giants, who will be the most desirable partners in executing the industry’s deals of the future?
Rowan Chapman, Managing Director, GE Ventures
Stephen Knight, M.D., President and Managing Partner, F-Prime Capital
Steve Schwartz, Vice President, Business Development & Strategy, 23andMe
Matthew Quinn, East Coast Managing Director, Healthcare and Life Sciences, Intel Corp.
MODERATOR: Carleen Hawn, Healthspottr CEO
This is a break for some, or the first of three curated 1-on-1 meeting sessions between fellow attendees and PwC hosts.
A leading industry CEO “in conversation” with PwC Partners. Moderated by Healthspottr’s Carleen Hawn. Includes Q&A.
Speakers share strategically important lessons from a recent transaction. Mr. Samuels shares insights from his decades-long career on Capitol Hill in helping companies navigate the legislative and regulatory maze of establishing novel payment and coverage mechanisms for their innovative therapeutics and devices.
Between the election cycle and health reform anew, Mr. Khosla shares his insights on the political and legislative developments — such as the tax extenders that are due to expire and the approaching debt ceiling — that could impact our industry in the coming year, and in particular, the way we invest in R&D. In conversation with Carleen Hawn. Joint Q&A with Dr. Jenkins to follow.
In her 20 years in biopharma, Dr. Jenkins has helped teams drive their innovations from scientific research through clinical development, regulatory approval and into the healthcare system globally. She will offer the entrepreneur’s perspective on the current trends influencing how we invest in R&D and bring our best ideas to market — including at Dimension, which celebrated its IPO on October 22. Joint Q&A with Jay Khosla.
This is the second of three curated 1-on-1 meeting sessions between fellow attendees and PwC hosts.
This is the third of three curated 1-on-1 meeting sessions between fellow attendees and PwC hosts.
PwC Principal Dimitri Drone and Healthspottr CEO Carleen Hawn
Stay current and connected. Our timely publications, webcasts and news alerts will help you not only react, but anticipate and adapt, in today’s evolving business environment.
As the health sector’s center of gravity shifts toward customers, savvy new players are moving fast to capitalize on the change. These new entrants are poised to shake up the industry, drawing billions of dollars in revenue from traditional healthcare organizations while building lucrative new markets in the burgeoning New Health Economy.
A deal announced with Genentech points the way for 23andMe, the personal genetics company backed by Facebook billionaire Yuri Milner and Google Ventures to become a sustainable business – even if the company’s discussions with the U.S. Food and Drug Administration stretch on for years.
Genetics. New manufacturing techniques. Demographic shifts. These are just a few of the forces changing the way industry players compete and collaborate. Are your analytics set up to help you quickly spot and evaluate new possibilities and impacts?
Q2 2015 saw a continued trend of deal activity with closed deal value of $72.2 billion from 46 transactions. Announced deals exceeded the prior quarter by 41% in value and 17% in volume.
The globalization of business models and dramatic changes in the way that businesses operate and compete have resulted in a shift in M&A strategy and execution. Joint ventures and strategic business alliances are an impactful way for companies to achieve their growth objectives to accompany organic growth and M&A.